Several studies found that increased EpCAM expression was associated with advanced stage and poor survival in patients with breast cancer, gallbladder cancer, ovarian cancer, Vater tubercle and esophageal cancer, and oral squamous cell carcinoma, because it acts as an inhibitor of E-cadherin. This evidence concerns the gene CDH1 and oral cavity squamous cell carcinoma.